Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 25 January 2017


INDICATIONS AND USAGE Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis.

In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery.

Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures.

Correction of Acidity of ACD Blood in Cardiac Bypass Surgery.

It is well known that ACD blood is acidic and becomes more acidic on storage.

Tromethamine effectively corrects this acidity.

Tham Solution may be added directly to the blood used to prime the pump-oxygenator.

When ACD blood is brought to a normal pH range the patient is spared an initial acid load.

Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear.

Metabolic Acidosis Associated with

Cardiac Arrest.

Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest.

It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts.

By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed.

In these cases, tromethamine was given intraventricularly.

It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine.

With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients.

The success in reinstitution of cardiac rhythm by this means probably has not been of the same order of magnitude as with the intraventricular route.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Pain, Agitation and Delirium (PAD) Management

Pain, Agitation and Delirium (PAD) Management

Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.

+ 4 more

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Load more

Related Content

Advisory information

CONTRAINDICATIONS Tham Solution (tromethamine injection) is contraindicated in uremia and anuria. In neonates it is also contraindicated in chronic respiratory acidosis and salicylate intoxication.
Special warnings and precautions

PRECAUTIONS Blood pH, PCO2 bicarbonate, glucose and electrolyte determinations should be performed before, during and after administration of Tham Solution.

While it has not been shown that the drug increases coagulation time in humans, this possibility should be kept in mind since this has been noted experimentally in dogs.

Do not administer unless solution is clear and seal is intact.

Discard unused portion.

Pregnancy Category C: Animal reproduction studies have not been conducted with tromethamine.

It is also not known whether tromethamine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Tromethamine should be given to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk.

Because many drugs are excreted in human milk, caution should be exercised when THAM Solution is administered to a nursing mother.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Studies with THAM

Solution have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

Pediatric Use: The safety and effectiveness of THAM Solution in pediatric patients is based on over 30 years ' clinical experience documented in the literature and on safety surveillance.

THAM Solution has been used to treat severe cases of metabolic acidosis with concurrent respiratory acidosis because it does not raise PCO2 as bicarbonate does in neonates and infants with respiratory failure.

It has also been used in neonates and infants with hypernatremia and metabolic acidosis to avoid the additional sodium given with the bicarbonate.

However, because the osmotic effects of THAM Solution are greater and large continuous doses are required, bicarbonate is preferred to THAM Solution in the treatment of acidotic neonates and infants with RDS. Hypoglycemia may occur when this product is used in premature and even full-term neonates.



Geriatric Use: Clinical studies of Tham solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Other reported clinical experience has not identified differences in response between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Adverse reactions

ADVERSE REACTIONS Generally, side effects have been infrequent.

Respiratory: Although the incidence of ventilatory depression is low, it is important to keep in mind that such depression may occur.

Respiratory depression may be more likely to occur in patients who have chronic hypoventilation or those who have been treated with drugs which depress respiration.

In patients with associated respiratory acidosis, tromethamine should be administered with mechanical assistance to ventilation.

Vascular: Extreme care should be taken to avoid perivascular infiltration.

Local tissue damage and subsequent sloughing may occur if extravasation occurs.

Chemical phlebitis and venospasm also have been reported.

Hematologic: Transient depression of blood glucose may occur.

Hepatic: Infusion via low-lying umbilical venous catheters has been associated with hepatocellular necrosis.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection extravasation and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Usage information

Dosing and administration

DOSAGE AND ADMINISTRATION Tham Solution (tromethamine injection) is administered by slow intravenous infusion, by addition to pump-oxygenator ACD blood or other priming fluid or by injection into the ventricular cavity during cardiac arrest.

For infusion by peripheral vein, a large needle should be used in the largest antecubital vein or an indwelling catheter placed in a large vein of an elevated limb to minimize chemical irritation of the alkaline solution during infusion.

Catheters are recommended.

Dosage and rate of administration should be carefully supervised to avoid overtreatment (alkalosis).

Pretreatment and subsequent determinations of blood values (e.g. pH, PCO2, PO2, glucose and electrolytes) and urinary output should be made as necessary to monitor dosage and progress of treatment.

In general, dosage should be limited to an amount sufficient to increase blood pH to normal limits (7.35 to 7.45) and to correct acid-base derangements.

The total quantity to be administered during the period of illness will depend upon the severity and progression of the acidosis.

The possibility of some retention of tromethamine, especially in patients with impaired renal function, should be kept in mind.

The intravenous dosage of Tham Solution (tromethamine injection) may be estimated from the buffer base deficit of the extracellular fluid in mEq/liter determined by means of the Siggaard-Andersen nomogram.

The following formula is intended as a general guide: Tham Solution (mL of 0.3_M) Required = Body Weight (kg) X Base Deficit (mEq/liter) X 1.1* Thus, a 70 kg patient with a buffer base deficit (“negative base excess”) of 5 mEq/liter would require 70 x 5 x 1.1 = 385 mL of Tham Solution containing 13.9 g (115 mEq) of tromethamine.

The need for administration of additional Tham Solution is determined by serial determinations of the existing base deficit.

* Factor of 1.1 accounts for an approximate reduction of 10 % in buffering capacity due to the presence of sufficient acetic acid to lower pH of the 0.3_M solution to approximately 8.6.

Correction of Metabolic Acidosis Associated with Cardiac Bypass Surgery: An adverse dose of approximately 9.0 mL/kg (324 mg/kg) has been used in clinical studies with Tham Solution (tromethamine injection).

This is equivalent to a total dose of 630 mL (189 mEq) for 70 kg patient.

A total single dose of 500 mL (150 mEq) is considered adequate for most adults.

Larger single doses (up to 1000 mL) may be required in unusually severe cases.

It is recommended that individual doses should not exceed 500 mg/kg (227 mg/lb) over a period of not less than one hour.

Thus, for a 70 kg (154 pound) patient the dose should not exceed a maximum of 35 g per hour (1078 mL of a 0.3_M solution).

Repeated determinations of pH and other clinical observations should be used as a guide to the need for repeat doses.

Correction of Acidity of ACD Blood in Cardiac Bypass Surgery: The pH of stored blood ranges from 6.80 to 6.22 depending upon the duration of storage.

The amount of Tham Solution used to correct this acidity ranges from 0.5 to 2.5 g (15 to 77 mL of a 0.3_M solution) added to each 500 mL of ACD blood used for priming the pump-oxygenator.

Clinical experience indicates that 2 g (62 mL of a 0.3_M solution) added to 500 mL of ACD blood is usually adequate.

Correction of Metabolic Acidosis Associated with Cardiac Arrest: In the treatment of cardiac arrest, Tham Solution should be given at the same time that other standard resuscitative measures, including manual systole, are being applied.

If the chest is open, Tham Solution is injected directly into the ventricular cavity.

From 2 to 6 g (62 to 185 mL of a 0.3_M solution) should be injected immediately.

Do not inject into the cardiac muscle.

If the chest is not open, from 3.6 to 10.8 g (111 to 333 mL of a 0.3_M solution) should be injected immediately into a larger peripheral vein.

Additional amounts may be required to control acidosis persisting after cardiac arrest is reversed.

Correction of Metabolic Acidosis Associated with RDS in Neonates and Infants: The initial dose of Tham Solution should be based on initial pH and birthweight amounting to approximately 1 mL per kg for each pH unit below 7.4.

Further doses have been given according to changes in PaO2, pH and PCO2.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.


Pregnancy and lactation
Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when THAM Solution is administered to a nursing mother.

More information

Category Value
Authorisation number NDA013025
Orphan designation No
Product NDC 0409-1593
Date Last Revised 26-01-2010
RXCUI 208655
Marketing authorisation holder Hospira, Inc.